Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results-A Retrospective, Comparative Study.

Burak Erden,Emine Baş,Selim Bölükbaşı,Akın Çakır

doi:10.1155/2019/8639243

Abstract

Purpose To compare one-year treatment outcomes of intravitreal aflibercept (IVA) and intravitreal ranibizumab (IVR) for treatment of myopic choroidal neovascularization (mCNV). Methods The medical records of a total of 30 eyes diagnosed with mCNV and underwent IVA or IVR treatment for a minimum one-year follow-up were studied retrospectively. All the subjects had an axial length >26 mm and received a 1 + PRN (pro re nata) regimen IVA or IVR. Best-corrected visual acuity (BCVA) and central macular thicknesses (CMT) on optical coherence tomography were evaluated before and after treatment. Results There were 12 eyes in IVA group, with a mean age of 60.0 ± 10.2 years. The mean BCVA significantly improved from baseline 1.54 ± 0.76 to 0.85 ± 0.61 and the mean CMT significantly decreased from baseline 384.3 ± 119.1 μm to 305.9 ± 75.4 μm to 305.9 ± 75.4 p : 0.024 and p : 0.024 and μm to 305.9 ± 75.4 μm to 305.9 ± 75.4 p : 0.024 and p : 0.024 and p : 0.024 and p : 0.024 and Conclusions Both IVA and IVR treatment modalities resulted in similar anatomical outcomes but IVA had better visual outcomes in treatment of mCNV.

Highlights

Myopic choroidal neovascularization is the major vision-threatening complication of pathologic myopia [1, 2].e pathologic myopia is characteristic with a myopic refractive error >6.0 diopters and axial length >26 mm and usually associated with typical degenerative changes of the fundus. e incidence of mCNVs ranges from 5.2% to 11.3% among the population with pathologic myopia [3, 4]
While 12 eyes constituted the intravitreal aflibercept (IVA) group, 18 eyes were included into the intravitreal ranibizumab (IVR) group. ere were no significant differences in means of gender distribution and mean age between both groups (p 0.574 and p 0.677, respectively). e mean ages of IVA and IVR groups were 60.0 ± 10.2 and 57.4 ± 13.1 years, respectively
Both groups were found statistically comparable in clinical parameters such as mean axial length and spherical equivalents of phakic eyes (28.4 ± 2.3 versus 29.3 ± 3; 9.4 ± 1.9 versus 9.6 ± 1.3). 3 eyes of 12 (25%) in IVA group and 4 eyes out of 18 (22%) in the IVR group had a history of a single intravitreal treatment beyond the six months before our study enrollment

Summary

Introduction

Myopic choroidal neovascularization (mCNV) is the major vision-threatening complication of pathologic myopia [1, 2].e pathologic myopia is characteristic with a myopic refractive error >6.0 diopters and axial length >26 mm and usually associated with typical degenerative changes of the fundus. e incidence of mCNVs ranges from 5.2% to 11.3% among the population with pathologic myopia [3, 4]. 3 eyes of 12 (25%) in IVA group and 4 eyes out of 18 (22%) in the IVR group had a history of a single intravitreal treatment (ranibizumab or bevacizumab) beyond the six months before our study enrollment. E mean BCVA in the IVA group significantly improved from baseline 1.54 ± 0.76 to 0.85 ± 0.61 at Month 12 (Wilcoxon signed rank test; p 0.024).

Results

Conclusion